文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Wahlbeck K, Ahokas A, Nikkilä H, Miettinen K, Rimón R

Department of Psychiatry, University of Helsinki, Finland.

Prog Neuropsychopharmacol Biol Psychiatry. 1997 May;21(4):591-9. doi: 10.1016/s0278-5846(97)00034-1.

The aim of the study was to replicate our earlier finding of elevated cerebrospinal fluid (CSF) angiotensin-converting enzyme (ACE) in neuroleptic-treated schizophrenia and to elucidate the correlations between CSF ACE, neuroleptic treatment, and psychotic symptoms in a longitudinal study. 2. Levels of ACE were measured in CSF and serum from 9 acutely psychotic schizophrenic patients at two separate points of time; within a few days of admission and at follow-up after 3-4 weeks. CSF ACE was also determined from 9 healthy controls. 3. The schizophrenic patients showed non-significantly higher levels of CSF ACE than the controls. Although a significant clinical improvement was observed and the neuroleptic medication was reduced during the follow-up period, there were no significant differences in serum or CSF ACE between the two observation points in the schizophrenia group.

本研究的目的是重复我们之前的发现，即接受抗精神病药物治疗的精神分裂症患者脑脊液（CSF）中的血管紧张素转换酶（ACE）升高，并在一项纵向研究中阐明CSF ACE、抗精神病药物治疗和精神病症状之间的相关性。2. 在两个不同时间点测量了9例急性精神病性精神分裂症患者脑脊液和血清中的ACE水平；入院后几天内以及3-4周后的随访时。还测定了9名健康对照者的脑脊液ACE。3. 精神分裂症患者的脑脊液ACE水平略高于对照组，但差异无统计学意义。尽管在随访期间观察到显著的临床改善且抗精神病药物用量减少，但精神分裂症组两个观察点之间的血清或脑脊液ACE水平无显著差异。

Wahlbeck K, Ahokas A, Nikkilä H, Miettinen K, Rimón R

Department of Psychiatry, University of Helsinki, Finland.

Prog Neuropsychopharmacol Biol Psychiatry. 1997 May;21(4):591-9. doi: 10.1016/s0278-5846(97)00034-1.

The aim of the study was to replicate our earlier finding of elevated cerebrospinal fluid (CSF) angiotensin-converting enzyme (ACE) in neuroleptic-treated schizophrenia and to elucidate the correlations between CSF ACE, neuroleptic treatment, and psychotic symptoms in a longitudinal study. 2. Levels of ACE were measured in CSF and serum from 9 acutely psychotic schizophrenic patients at two separate points of time; within a few days of admission and at follow-up after 3-4 weeks. CSF ACE was also determined from 9 healthy controls. 3. The schizophrenic patients showed non-significantly higher levels of CSF ACE than the controls. Although a significant clinical improvement was observed and the neuroleptic medication was reduced during the follow-up period, there were no significant differences in serum or CSF ACE between the two observation points in the schizophrenia group.

本研究的目的是重复我们之前的发现，即接受抗精神病药物治疗的精神分裂症患者脑脊液（CSF）中的血管紧张素转换酶（ACE）升高，并在一项纵向研究中阐明CSF ACE、抗精神病药物治疗和精神病症状之间的相关性。2. 在两个不同时间点测量了9例急性精神病性精神分裂症患者脑脊液和血清中的ACE水平；入院后几天内以及3-4周后的随访时。还测定了9名健康对照者的脑脊液ACE。3. 精神分裂症患者的脑脊液ACE水平略高于对照组，但差异无统计学意义。尽管在随访期间观察到显著的临床改善且抗精神病药物用量减少，但精神分裂症组两个观察点之间的血清或脑脊液ACE水平无显著差异。